1.51
price down icon0.11%   -0.0017
after-market Dopo l'orario di chiusura: 1.56 0.05 +3.31%
loading
Precedente Chiudi:
$1.5117
Aprire:
$1.5485
Volume 24 ore:
23,604
Relative Volume:
0.15
Capitalizzazione di mercato:
$39.71M
Reddito:
-
Utile/perdita netta:
$-13.27M
Rapporto P/E:
-9.2073
EPS:
-0.164
Flusso di cassa netto:
$-7.70M
1 W Prestazione:
+23.77%
1M Prestazione:
+8.63%
6M Prestazione:
+19.84%
1 anno Prestazione:
+4.38%
Intervallo 1D:
Value
$1.50
$1.5786
Intervallo di 1 settimana:
Value
$1.14
$1.7099
Portata 52W:
Value
$0.8075
$1.74

Okyo Pharma Limited Stock (OKYO) Company Profile

Name
Nome
Okyo Pharma Limited
Name
Telefono
-
Name
Indirizzo
-
Name
Dipendente
3
Name
Cinguettio
Name
Prossima data di guadagno
2024-09-30
Name
Ultimi documenti SEC
Name
OKYO's Discussions on Twitter

Confronta OKYO con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
OKYO
Okyo Pharma Limited
1.51 39.71M 0 -13.27M -7.70M -0.164
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
493.84 122.76B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
602.64 61.38B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
614.76 36.37B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
251.56 30.12B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
244.90 24.70B 3.81B -644.79M -669.77M -6.24

Okyo Pharma Limited Borsa (OKYO) Ultime notizie

pulisher
Apr 23, 2025

OKYO Pharma Announces First Patient Dosed in the First Clinical Trial to Treat Neuropathic Corneal Pain - ADVFN

Apr 23, 2025
pulisher
Apr 22, 2025

OKYO Pharma Announces Start of Phase 2 Clinical Trial to Treat Patients with Neuropathic Corneal Pain - ADVFN

Apr 22, 2025
pulisher
Apr 08, 2025

Kyverna Therapeutics (NASDAQ:KYTX) and OKYO Pharma (NASDAQ:OKYO) Financial Review - Defense World

Apr 08, 2025
pulisher
Apr 05, 2025

OKYO Pharma CEO discusses FDA Fast Track filing for urcosimodICYMI - Proactive financial news

Apr 05, 2025
pulisher
Apr 01, 2025

OKYO Pharma achieves key stability milestone for Urcosimod in clinical development - Proactive financial news

Apr 01, 2025
pulisher
Mar 31, 2025

OKYO Stock Price and Chart — NASDAQ:OKYO - TradingView

Mar 31, 2025
pulisher
Mar 31, 2025

OKYO Pharma Announces Positive Data in Long-Term Stability of Urcosimod - GlobeNewswire

Mar 31, 2025
pulisher
Mar 31, 2025

Small cap wrap: OKYO Pharma, Charbone Hydrogen, Hillcrest... - Proactive financial news

Mar 31, 2025
pulisher
Mar 31, 2025

OKYO Pharma reports long-term benefits of its neuropathic corneal pain treatment - Seeking Alpha

Mar 31, 2025
pulisher
Mar 31, 2025

OKYO Pharma releases positive long-term stability data for urcosimod in neuropathic corneal pain - Ophthalmology Times

Mar 31, 2025
pulisher
Mar 31, 2025

Urcosimod shows promise in long-term stability test - Investing.com

Mar 31, 2025
pulisher
Mar 31, 2025

OKYO Pharma confirms stability of drug candidate By Investing.com - Investing.com South Africa

Mar 31, 2025
pulisher
Mar 31, 2025

Urcosimod shows promise in long-term stability test By Investing.com - Investing.com India

Mar 31, 2025
pulisher
Mar 31, 2025

OKYO Pharma Achieves Key Stability Milestone for Urcosimod - TipRanks

Mar 31, 2025
pulisher
Mar 31, 2025

OKYO Pharma confirms stability of drug candidate - Investing.com

Mar 31, 2025
pulisher
Mar 31, 2025

OKYO Pharma reports long-term shelf stability of corneal pain treatment - Proactive financial news

Mar 31, 2025
pulisher
Mar 21, 2025

Dauntless Investment Group, LLC Acquires Significant Stake in OK - GuruFocus

Mar 21, 2025
pulisher
Mar 19, 2025

OKYO Pharma (NASDAQ:OKYO) versus IN8bio (NASDAQ:INAB) Head-To-Head Analysis - Defense World

Mar 19, 2025
pulisher
Mar 19, 2025

OKYO Pharma Limited (NASDAQ:OKYO) Sees Significant Growth in Short Interest - Defense World

Mar 19, 2025
pulisher
Mar 17, 2025

Okyo Pharma Limited Announces Filing of A Patent Application Covering the Use of Chemerin and Associated Analogues to Treat “Cytokine Storm” Associated with COVID-19 and ARDS - marketscreener.com

Mar 17, 2025
pulisher
Mar 10, 2025

OKYO Pharma seeks FDA fast track for eye pain treatment By Investing.com - Investing.com Australia

Mar 10, 2025
pulisher
Mar 10, 2025

OKYO Pharma seeks FDA Fast Track for eye pain drug By Investing.com - Investing.com Australia

Mar 10, 2025
pulisher
Mar 10, 2025

OKYO Pharma seeks FDA fast track for eye pain treatment - Investing.com India

Mar 10, 2025
pulisher
Mar 10, 2025

OKYO Pharma seeks FDA Fast Track designation for neuropathic corneal pain treatment | NASDAQ:OKYO - Proactive Investors

Mar 10, 2025
pulisher
Mar 10, 2025

OKYO Pharma Seeks FDA Fast Track for Urcosimod in Treating Neuropathic Corneal Pain - TipRanks

Mar 10, 2025
pulisher
Mar 10, 2025

OKYO Pharma seeks FDA Fast Track for eye pain drug - Investing.com

Mar 10, 2025
pulisher
Mar 10, 2025

OKYO Pharma Files for Fast Track Designation with FDA for Urcosimod to Treat Neuropathic Corneal Pain - GlobeNewswire

Mar 10, 2025
pulisher
Mar 10, 2025

OKYO Pharma seeks FDA Fast Track designation for neuropathic corneal pain treatment - Proactive financial news

Mar 10, 2025
pulisher
Mar 05, 2025

OKYO Pharma secures $1.4 million non-dilutive funding - MSN

Mar 05, 2025
pulisher
Mar 05, 2025

Comparing Immunovant (NASDAQ:IMVT) & OKYO Pharma (NASDAQ:OKYO) - Defense World

Mar 05, 2025
pulisher
Feb 20, 2025

OKYO Pharma advances neuropathic corneal pain drug trial - MSN

Feb 20, 2025
pulisher
Feb 19, 2025

OKYO Pharma (NASDAQ:OKYO) Receives “Buy” Rating from HC Wainwright - Defense World

Feb 19, 2025
pulisher
Feb 18, 2025

H.C. WAINWRIGHT MAINTAINS BUY RATING ON OKYO PHARMA STOCK By Investing.com - Investing.com Australia

Feb 18, 2025
pulisher
Feb 18, 2025

H.C. WAINWRIGHT MAINTAINS BUY RATING ON OKYO PHARMA STOCK - Investing.com India

Feb 18, 2025
pulisher
Feb 17, 2025

Contrasting OKYO Pharma (NASDAQ:OKYO) and CG Oncology (NASDAQ:CGON) - Defense World

Feb 17, 2025
pulisher
Feb 14, 2025

Buy Recommendation for OKYO Pharma Driven by Promising Urcosimod Efficacy and Market Potential - TipRanks

Feb 14, 2025
pulisher
Feb 14, 2025

Okyo Pharma's OK-101 renamed urcosimod for eye pain - MSN

Feb 14, 2025
pulisher
Feb 12, 2025

H.C. Wainwright maintains Buy on OKYO Pharma with $7 target - MSN

Feb 12, 2025
pulisher
Feb 12, 2025

OKYO Pharma’s lead asset receives USAN designation "urcosimod By Investing.com - Investing.com Nigeria

Feb 12, 2025
pulisher
Feb 12, 2025

OKYO Pharma's lead asset receives USAN designation "urcosimod - MSN

Feb 12, 2025
pulisher
Feb 12, 2025

OKYO Pharma has dry eyes as a lucrative prize in its sights - Proactive Investors UK

Feb 12, 2025
pulisher
Feb 12, 2025

Okyo Pharma's OK-101 renamed urcosimod for eye pain By Investing.com - Investing.com South Africa

Feb 12, 2025
pulisher
Feb 12, 2025

OKYO Pharma's lead asset receives USAN designation "urcosimod By Investing.com - Investing.com UK

Feb 12, 2025
pulisher
Feb 12, 2025

OKYO Pharma Announces OK-101 Officially Assigned USAN : Urcosimod - GlobeNewswire

Feb 12, 2025
pulisher
Feb 12, 2025

OKYO Pharma’s Lead Asset OK-101 Receives USAN as Urcosimod - TipRanks

Feb 12, 2025

Okyo Pharma Limited Azioni (OKYO) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$20.59
price up icon 0.24%
$69.69
price up icon 1.06%
$32.20
price up icon 0.53%
$23.46
price down icon 36.06%
$102.02
price down icon 15.36%
biotechnology ONC
$244.90
price down icon 4.40%
Capitalizzazione:     |  Volume (24 ore):